ResMed announced today that it launched its new AirTouch N30i continuous positive airway pressure (CPAP) mask.

Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...

As the title of this article gave away, that company is ResMed (NYSE:RMD), a fast-growing ... and a shift from air freight to cheaper sea freight. Additionally, margins benefitted from the ...

Wolfe Research analyst Michael Polark downgraded the rating on Resmed (RMD – Research Report) to a Sell yesterday, setting a price target of $180.00. Michael Polark has given his Sell rating due ...

Despite decades of progress, the air quality in the United States has started to decline over the past few years, according to data in the Environmental Protection Agency's 2024 "Our Nation’s ...

NEW YORK — The morning after presenting an upbeat outlook to analysts in a gilded hall in the New York Stock Exchange building, Mick Farrell, the CEO of ResMed, looked refreshed, despite a post ...

ResMed (RMD) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of ...

But ResMed, which makes sleep apnea devices, sees an opportunity. The device maker has started presenting data suggesting GLP-1 users are more likely to go on to use CPAP eventually.

ResMed Inc.’s RMD growth is backed by its impressive global Mask sales growth. Of late, the company has been experiencing increased Device sales, reflecting the ongoing combined availability of ...

Investors seem to be signalling out ResMed for punishment. Whilst the ASX 200 is having a bad day, it's been far worse for Resmed shares. This ASX 200 healthcare stock closed at $36.25 a share ...

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...